Homburger advises ADC Therapeutics SA in its follow-on public offering in the United States

On September 23, 2020, ADC Therapeutics SA (NYSE: ADCT), a Swiss-based late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of antibody drug conjugates, announced the pricing of its upsized follow-on public offering of shares in the United States, thus raising gross proceeds of USD 204 m. In addition, certain existing shareholders had granted the underwriters an option to purchase additional shares („greenshoe“) for an aggregate amount of up to USD 30.6 m.

Homburger advises ADC Therapeutics SA in this matter. The Homburger team is led by partner Dieter Gericke (Corporate / M&A) and includes lead associate Daniel Häusermann (Corporate / M&A), partners Reto Heuberger (Tax) and Benjamin Leisinger (Banking and Finance), as well as associates Olivier Baum (Banking and Finance), Estelle Piccard (Corporate / M&A) and Marc Vogelsang (Tax).